Clinical Scorecard: FDA expands treatment in nephrotic syndrome
At a Glance
| Category | Detail |
|---|---|
| Condition | idiopathic nephrotic syndrome |
| Key Mechanisms | characterized by urinary protein loss leading to low blood albumin levels and potential complications such as high cholesterol, infections, and blood clots that may obstruct small blood vessels. |
| Target Population | adult and pediatric patients aged 2 years and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome in remission |
| Care Setting | clinical trial setting |
Key Highlights
- Obinutuzumab approved to reduce relapse risk in nephrotic syndrome
- Efficacy assessed in a phase 3 randomized open-label multicenter controlled trial with 85 patients
- 73% of patients on obinutuzumab met primary efficacy endpoint
- Common side effects include infections and neutropenia
- Obinutuzumab previously approved for certain cancers and lupus nephritis
Guideline-Based Recommendations
Diagnosis
- Diagnosis of idiopathic nephrotic syndrome requires normal urine protein levels and absence of swelling.
Management
- Obinutuzumab administered intravenously on specified days for treatment.
Monitoring & Follow-up
- Monitor for hepatitis B virus reactivation and progressive multifocal leukoencephalopathy.
Risks
- Potential complications include infections, infusion-related reactions, and neutropenia.
Patient & Prescribing Data
patients aged 2 years and older with frequently relapsing or steroid-dependent idiopathic nephrotic syndrome
Obinutuzumab shows a statistically significant improvement in maintaining remission compared to standard-of-care treatment.
Clinical Best Practices
- Ensure patients are in complete remission before initiating obinutuzumab treatment.
- Educate patients about potential side effects and the importance of monitoring.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
